News and Trends 18 Sep 2023 Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities The U.K. is rejoining the European Union’s (EU’s) $100 billion research program Horizon Europe, after being locked out of the deal amid post Brexit tensions for more than two years. This comes after months of negotiations between the U.K. government and the EU, in an attempt to broaden opportunities for researchers in the U.K.. British […] September 18, 2023 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2023 Biogen acquiring Reata Pharmaceuticals for $7.3B Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […] July 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS Pharma Inc.’s NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy. The breakthrough designation is based on results from a first-in-human, investigator-initiated clinical trial conducted in Japan. In June 2023, NS-089/NCNP-02 was granted Rare […] July 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 Could a natural sweetener from hydrangeas treat Alzheimer’s disease? Amyloid β (Aβ) aggregation is primarily responsible for the development of Alzheimer’s disease (AD). In a new mouse model study, South Korean researchers investigated the effect of phyllodulcin — a natural sweetener found in the hydrangea plant — in inhibiting Aβ accumulation. The results suggest that phyllodulcin effectively inhibits Aβ accumulation and decomposes the pre-aggregated […] July 28, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 New CHAIN Biotech funding to aid CADD therapeutic platform CHAIN Biotechnology Limited has developed a therapeutic approach based on engineering a probiotic strain of Clostridium to deliver oral vaccines and therapeutics. Its Clostridium Assisted Drug Development platform (CADD) technology is a live therapeutic that employs a triple mode of action, incorporating mucosal and systemic immune responses alongside microbiome enhancement, and is delivered via stable, […] July 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Recbio shingles vaccine clinical trial approved Jiangsu Recbio Technology Co., Ltd. has received notice of acceptance from China’s National Medical Products Administration (NMPA) to start a clinical trial for its self-developed novel adjuvanted recombinant shingles vaccine, REC610. Within 60 days from the date of acceptance, the company may carry out clinical trials in accordance with the submitted plan if no negative […] July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Epsilogen completes first clinical trial of IgE antibody to treat cancer Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target […] July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Medicxi announces $400M fund for life science companies Medicxi, a European life sciences investment firm, has launched its $400 million Medicxi IV fund. The new fund will support companies with clear product visions to deliver transformative therapies for patients. Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna […] July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2023 Diabetes drug could promote healthy aging A research team from the School of Public Health, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has provided genetic evidence that metformin might promote healthy aging using a cohort study of more than 300,000 participants of European descent (UK Biobank). The proof-of-concept work supports further clinical research into the drug repositioning […] July 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Triastek sees positive results from printed oral treatment for ulcerative colitis Triastek, Inc. has completed its first in human study of its third 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC). Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug release. The administration of […] July 25, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Can the microbiome help the fight against infections? Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming a relationship that can range from mutually beneficial to pathogenic. To safeguard against harmful pathogens and maintain the presence of beneficial microorganisms, animals have evolved various defenses.One is small antimicrobial peptides (AMPs), small peptides that combat invading microbes. AMPs are […] July 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial Molecure S.A. has received clearance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application to conduct phase II clinical testing of OATD-01. The announcement follows the company closing a secondary public offering and entering into subscription agreements for all 2,776,000 H-shares offered by way of private placement, within the […] July 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email